CD8-Positive T-Lymphocytes
"CD8-Positive T-Lymphocytes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.
| Descriptor ID |
D018414
|
| MeSH Number(s) |
A11.118.637.555.567.569.220 A15.145.229.637.555.567.569.220 A15.382.490.555.567.569.220
|
| Concept/Terms |
CD8-Positive T-Lymphocytes- CD8-Positive T-Lymphocytes
- CD8 Positive T Lymphocytes
- CD8-Positive T-Lymphocyte
- T-Lymphocyte, CD8-Positive
- T-Lymphocytes, CD8-Positive
- T8 Lymphocytes
- Lymphocyte, T8
- Lymphocytes, T8
- T8 Lymphocyte
- T8 Cells
- Cell, T8
- Cells, T8
- T8 Cell
- CD8-Positive Lymphocytes
- CD8 Positive Lymphocytes
- CD8-Positive Lymphocyte
- Lymphocyte, CD8-Positive
- Lymphocytes, CD8-Positive
Suppressor T-Lymphocytes, CD8-Positive- Suppressor T-Lymphocytes, CD8-Positive
- CD8-Positive Suppressor T-Lymphocyte
- CD8-Positive Suppressor T-Lymphocytes
- Suppressor T Lymphocytes, CD8 Positive
- Suppressor T-Lymphocyte, CD8-Positive
- T-Lymphocyte, CD8-Positive Suppressor
- T-Lymphocytes, CD8-Positive Suppressor
- Suppressor T-Cells, CD8-Positive
- CD8-Positive Suppressor T-Cell
- CD8-Positive Suppressor T-Cells
- Suppressor T Cells, CD8 Positive
- Suppressor T-Cell, CD8-Positive
- T-Cell, CD8-Positive Suppressor
- T-Cells, CD8-Positive Suppressor
|
Below are MeSH descriptors whose meaning is more general than "CD8-Positive T-Lymphocytes".
Below are MeSH descriptors whose meaning is more specific than "CD8-Positive T-Lymphocytes".
This graph shows the total number of publications written about "CD8-Positive T-Lymphocytes" by people in this website by year, and whether "CD8-Positive T-Lymphocytes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 4 | 5 |
| 1996 | 0 | 2 | 2 |
| 1997 | 3 | 2 | 5 |
| 1998 | 7 | 5 | 12 |
| 1999 | 7 | 5 | 12 |
| 2000 | 3 | 7 | 10 |
| 2001 | 13 | 8 | 21 |
| 2002 | 9 | 3 | 12 |
| 2003 | 14 | 7 | 21 |
| 2004 | 10 | 9 | 19 |
| 2005 | 14 | 4 | 18 |
| 2006 | 5 | 6 | 11 |
| 2007 | 4 | 6 | 10 |
| 2008 | 6 | 8 | 14 |
| 2009 | 6 | 4 | 10 |
| 2010 | 9 | 8 | 17 |
| 2011 | 6 | 7 | 13 |
| 2012 | 7 | 11 | 18 |
| 2013 | 7 | 10 | 17 |
| 2014 | 10 | 5 | 15 |
| 2015 | 5 | 11 | 16 |
| 2016 | 3 | 7 | 10 |
| 2017 | 7 | 7 | 14 |
| 2018 | 5 | 8 | 13 |
| 2019 | 13 | 10 | 23 |
| 2020 | 7 | 14 | 21 |
| 2021 | 11 | 10 | 21 |
| 2022 | 8 | 13 | 21 |
| 2023 | 9 | 12 | 21 |
| 2024 | 9 | 5 | 14 |
To return to the timeline,
click here.
Below are the most recent publications written about "CD8-Positive T-Lymphocytes" by people in Profiles.
-
NK cells restrain cytotoxic CD8+ T cells in the submandibular gland via PD-1-PD-L1. Sci Immunol. 2024 Dec 20; 9(102):eadl2967.
-
Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity. Cancer Immunol Res. 2024 Nov 04; 12(11):1525-1541.
-
Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance. Clin Cancer Res. 2024 Oct 01; 30(19):4450-4463.
-
Characterization of double-negative T cells in colorectal cancers and their corresponding lymph nodes. Oncoimmunology. 2024; 13(1):2373530.
-
Tumor-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment. Nat Cancer. 2024 Jul; 5(7):1045-1062.
-
The CD8+ TÂ cell tolerance checkpoint triggers a distinct differentiation state defined by protein translation defects. Immunity. 2024 06 11; 57(6):1324-1344.e8.
-
Pregnancy dedifferentiates memory CD8+ T cells into hypofunctional cells with exhaustion-enriched programs. JCI Insight. 2024 May 21; 9(13).
-
Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy. Cancer Cell. 2024 Jun 10; 42(6):1032-1050.e10.
-
Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy. Cell Rep. 2024 05 28; 43(5):114141.
-
One CD4+TCR and One CD8+TCR Targeting Autochthonous Neoantigens Are Essential and Sufficient for Tumor Eradication. Clin Cancer Res. 2024 Apr 15; 30(8):1642-1654.